MAPT and Alzheimer disease: In fact, they proved that the inhibition of PRMT4 in mice bearing tau- and Aβ -producing transgenic mutations (3xTg-AD) resulted in a restored CBF, an increment in NO metabolite production, and also an increase in the functional measurements of NOS uncoupling (reduced 3-nitrotyrosine).